Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:FSTX F-star Therapeutics (FSTX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About F-star Therapeutics Stock (NASDAQ:FSTX) 30 days 90 days 365 days Advanced Chart Ad WealthPressThe only candlestick pattern worth a darnIt’s widely known that 80% of daily market action is driven by Wall Street algorithms… Now, most people think of the algorithms are “bad” When in reality, they are neither good nor bad… They are simply programmed to buy and sell certain stocks over and over again… But here is the thing… They are predictable… They typically buy the same stocks at the same levels over and over again…Follow this link here and enter your email address to sign up… Get F-star Therapeutics alerts:Sign Up Key Stats Today's Range$7.12▼$7.1250-Day Range$4.42▼$7.1252-Week Range$2.07▼$7.12VolumeN/AAverage Volume709,213 shsMarket Capitalization$156.50 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewF-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. It focuses on transforming the lives of patients with cancer through the development of tetravalent mAb2 bispecific antibodies. The firm's product candidate, FS118, simultaneously targets two immune checkpoint receptors, LAG-3 and PD-L1, to directly address known tumor evasion pathways. The company was founded on October 7, 2002 and is headquartered in Cambridge, the United Kingdom.Read More… The only candlestick pattern worth a darn (Ad)It’s widely known that 80% of daily market action is driven by Wall Street algorithms… Now, most people think of the algorithms are “bad” When in reality, they are neither good nor bad… They are simply programmed to buy and sell certain stocks over and over again… But here is the thing… They are predictable… They typically buy the same stocks at the same levels over and over again…Follow this link here and enter your email address to sign up… Receive FSTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for F-star Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address FSTX Stock News HeadlinesAstria Therapeutics price target raised to $28 from $26 at OppenheimerNovember 14 at 4:40 PM | markets.businessinsider.comLake Street Remains a Buy on Aquestive Therapeutics (AQST)October 25, 2024 | markets.businessinsider.comHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.November 17, 2024 | Insiders Exposed (Ad)Starton Therapeutics Announces Successful Feasibility Demonstration of STAR-LLD Using BD Evolve™ On-Body InjectorSeptember 18, 2024 | markets.businessinsider.comBicara Therapeutics Rises 39% in Debut on NasdaqSeptember 15, 2024 | marketwatch.comAnalysts Offer Insights on Healthcare Companies: Poseida Therapeutics (PSTX) and SAGE Therapeutics (SAGE)July 25, 2024 | markets.businessinsider.comBuy Rating for Astria Therapeutics: Promising STAR-0215 Outpaces Competitors with Strategic Trials and Market PotentialMay 10, 2024 | markets.businessinsider.comAstria Therapeutics: Strong Buy Rating on Robust Finances and Promising Clinical TrialsMay 10, 2024 | markets.businessinsider.comSee More Headlines FSTX Stock Analysis - Frequently Asked Questions How were F-star Therapeutics' earnings last quarter? F-star Therapeutics, Inc. (NASDAQ:FSTX) announced its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.58) by $0.06. The firm earned $0.75 million during the quarter, compared to analyst estimates of $7.18 million. What other stocks do shareholders of F-star Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that F-star Therapeutics investors own include New Age Brands (NF), Aurora Cannabis (ACB), Trican Well Service (TCW), Meta Platforms (META), NIO (NIO), Plug Power (PLUG) and Copper Mountain Mining (CMMC). Company Calendar Last Earnings11/10/2021Today11/16/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:FSTX CUSIPN/A CIK1566373 Webwww.f-star.com Phone441223497400Fax508-381-0347Employees84Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-31,280,000.00 Net MarginsN/A Pretax Margin-213.97% Return on Equity-57.08% Return on Assets-42.40% Debt Debt-to-Equity Ratio0.15 Current Ratio3.38 Quick Ratio3.38 Sales & Book Value Annual Sales$21.17 million Price / Sales7.39 Cash FlowN/A Price / Cash FlowN/A Book Value$4.70 per share Price / Book1.51Miscellaneous Outstanding Shares21,980,000Free Float21,279,000Market Cap$156.50 million OptionableNot Optionable Beta0.85 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report This page (NASDAQ:FSTX) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding F-star Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share F-star Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
